Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Magnetic resonance-guided prostate interventions

We review our experience using an open 0.5-T magnetic resonance (MR) interventional unit to guide procedures in the prostate. This system allows access to the patient and real-time MR imaging simultaneously and has made it possible to perform prostate biopsy and brachytherapy under MR guidance. We review MR imaging of the prostate and its use in targeted therapy, and describe our use of image processing methods such as image registration to further facilitate precise targeting. We describe current developments with a robot assist system being developed to aid radioactive seed placement.

hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer

Background

The genetic and molecular mechanisms responsible for and associated with the development and progression of prostate malignancy are largely unidentified. The peripheral zone is the major region of the human prostate gland where malignancy develops. The normal peripheral zone glandular epithelium has the unique function of accumulating high levels of zinc. In contrast, the ability to accumulate zinc is lost in the malignant cells. The lost ability of the neoplastic epithelial cells to accumulate zinc is a consistent factor in their development of malignancy. Recent studies identified ZIP1 (SLC39A1) as an important zinc transporter involved in zinc accumulation in prostate cells. Therefore, we investigated the possibility that down-regulation of hZIP1 gene expression might be involved in the inability of malignant prostate cells to accumulate zinc. To address this issue, the expression of hZIP1 and the depletion of zinc in malignant versus non-malignant prostate glands of prostate cancer tissue sections were analyzed. hZIP1 expression was also determined in malignant prostate cell lines.

Results

hZIP1 gene expression, ZIP1 transporter protein, and cellular zinc were prominent in normal peripheral zone glandular epithelium and in benign hyperplastic glands (also zinc accumulating glands). In contrast, hZIP1 gene expression and transporter protein were markedly down-regulated and zinc was depleted in adenocarcinomatous glands and in prostate intra-epithelial neoplastic foci (PIN). These changes occur early in malignancy and are sustained during its progression in the peripheral zone. hZIP1 is also expressed in the malignant cell lines LNCaP, PC-3, DU-145; and in the nonmalignant cell lines HPr-1 and BPH-1.

Conclusion

The studies clearly establish that hZIP1 gene expression is down regulated and zinc is depleted in adenocarcinomatous glands. The fact that all the malignant cell lines express hZIP1 indicates that the down-regulation in adenocarcinomatous glands is likely due to in situ gene silencing. These observations, coupled with the numerous and consistent reports of loss of zinc accumulation in malignant cells in prostate cancer, lead to the plausible proposal that down regulation of hZIP1 is a critical early event in the development prostate cancer.

The fast Padé transform in magnetic resonance spectroscopy for potential improvements in early cancer diagnostics

The convergence rates of the fast Padé transform (FPT) and the fast Fourier transform (FFT) are compared. These two estimators are used to process a time-signal encoded at 4 T by means of one-dimensional magnetic resonance spectroscopy (MRS) for healthy human brain. It is found systematically that at any level of truncation of the full signal length, the clinically relevant resonances that determine concentrations of metabolites in the investigated tissue are significantly better resolved in the FPT than in the FFT. In particular, the FPT has a better resolution than the FFT for the same signal length. Moreover, the FPT can achieve the same resolution as the FFT by using twice shorter signals. Implications of these findings for two-dimensional magnetic resonance spectroscopy as well as for two- and three-dimensional magnetic resonance spectroscopic imaging are highlighted. Self-contained cross-validation of all the results from the FPT is secured by using two conceptually different, equivalent algorithms (inside and outside the unit-circle), that are both valid in the entire complex frequency plane. The difference between the results from these two variants of the FPT is indistinguishable from the background noise. This constitutes robust error analysis of proven validity. The FPT shows promise in applications of MRS for early cancer detection.

Zinc and zinc transporters in normal prostate and the pathogenesis of prostate cancer

Zinc is an essential metal for all cells. It plays a role in a wide variety of physiological and biochemical processes. In the prostate epithelial cell the accumulation of high cellular zinc is a specialized function that is necessary for these cells to carry out the major physiological functions of production and secretion of citrate. The production of citrate and its secretion into prostatic fluid is a differentiated function of the prostate epithelial cells that is apparently important for reproduction. The loss of citrate and zinc accumulation is the most consistent and persistent characteristic of prostate malignancy. This characteristic of prostate cancer indicates that the lost ability of the malignant cells to accumulate zinc and citrate is an important factor in the development and progression of malignancy. The lost ability of the epithelial cells to accumulate zinc and thus to also accumulate citrate is the result of decreased expression of specific zinc uptake transporters. The purpose of this presentation is to review the current understanding of zinc and zinc homeostasis in the prostate and the role of zinc and zinc transporters in the normal function of the prostate and the pathogenesis of prostate cancer.

Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T

Magnetic resonance spectroscopic imaging (MRSI) has proven to be a powerful tool for the metabolic characterization of prostate cancer in patients before and following therapy. The metabolites that are of particular interest are citrate and choline because an increased choline-to-citrate ratio can be used as a marker for cancer. High-field systems offer the advantage of improved spectral resolution as well as increased magnetization. Initial attempts at extending MRSI methods to 3 T have been confounded by the J-modulation of the citrate resonances. A new pulse sequence is presented that controls the J-modulation of citrate at 3 T such that citrate is upright, with high amplitude, at a practical echo time. The design of short (14 ms) spectral-spatial refocusing pulses and trains of nonselective refocusing pulses are described. Phantom studies and simulations showed that upright citrate with negligible sidebands is observed at an echo time of 85 ms. Studies in a human subject verified that this behavior is reproduced in vivo and demonstrated that the water and lipid suppression of the new pulse sequence are sufficient for application in prostate cancer patients.

Optimizing PRESS localized citrate detection at 3 Tesla

Analytical methods are used to characterize the response of the strongly coupled two-spin system of citrate to point-resolved spectroscopy (PRESS)-based sequences at 3 T. The signal output is analyzed line by line, as well as in the Cartesian product operator basis. Patterns with a periodicity of 80.9 ms are identified. Furthermore, it is shown that at TE = n . 80.9 ms (n in {0,1,2,...}), the spin evolution can be described without direct reference to strong coupling terms. The theoretical results are found to be in good agreement with in vivo experiments. These results can be used to design protocols for prostate MRS and MRSI at 3 T, and give guidelines for optimizing spin-echo-based acquisition schemes for detecting two-spin systems at arbitrary field strengths.

PSF-choice: a novel MRI method for shaping point-spread functions in phase-encoding dimensions

An imaging method to obtain arbitrary point-spread functions (PSFs) in phase-encoding dimensions is described. This method, called PSF-Choice, is particularly relevant for applications, such as spectroscopic imaging, in which only a very few phase encodes are acquired and ringing artifact can be a serious problem. PSF-Choice uses partial 2D RF excitations to produce aliased excitations that are encoded using standard phase-encoding gradients. Theoretically, the PSF of the reconstructed result depends only on the RF excitation profile. Simulations demonstrate that a Gaussian-like PSF can be achieved, eliminating the side lobes that are associated with ringing artifact. It is further shown that neither the spatial resolution (as represented by the width of the PSF) nor the signal-to-noise ratio (SNR) of the method is adversely affected when compared to standard phase encoding. In the sense that the same number of encodes are required as with standard phase encoding, temporal resolution is also maintained. Phantom experiments demonstrate the initial feasibility of the method to eliminate ringing artifact.

Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate

PURPOSE

To compare the apparent diffusion coefficient (ADC) values of prostate cancer in both the peripheral zone (PZ) and the transition zone (TZ) with those of benign tissue in the same zone using echo-planar diffusion weighted imaging with a parallel imaging technique.

MATERIALS AND METHODS

A total of 29 consecutive male patients (mean age 61.3 years, age range 53-88 years) with suspected prostate cancer were referred for MR imaging. All patients underwent transrectal ultrasound (TRUS)-guided biopsy of the prostate after MR imaging at 1.5 T, including ADC. For each patient, seven to 10 specimens were obtained from the prostate, and regions of interest (ROIs) were drawn on the ADC map by referring to the urologist's illustration of TRUS-guided biopsy sites. ADC values of cancerous tissue in both the PZ and TZ were compared to those of noncancerous tissue in the same zone.

RESULTS

Out of 29 patients, 23 had cancer tissue. In the 23 patients with cancer, the mean ADC value of all cancer ROIs and that of all noncancer ROIs, respectively, were 1.11 +/- 0.41 x 10(-3) and 1.68 +/- 0.40 x 10(-3) mm(2)/second (values are mean +/- SD) (P < 0.01). The mean ADC value of TZ cancer ROIs and that of TZ noncancer ROIs, respectively, were 1.13 +/- 0.42 x 10(-3) and 1.58 +/- 0.37 x 10(-3) mm(2)/second (P < 0.01).

CONCLUSIONS

ADC measurement with a parallel imaging technique showed that ADC values of prostate cancer in both the PZ and TZ were significantly lower than those of benign tissue in the PZ and TZ, respectively.

Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique

AIMS

To develop a method of processing non-formalin fixed prostate specimens removed at radical prostatectomy to obtain fresh tissue for research and for correlating diagnostic and molecular results with preoperative imaging.

METHODS/RESULTS

The method involves a prostate slicing apparatus comprising a tissue slicer with a series of juxtaposed planar stainless steel blades linked to a support, and a cradle adapted to grip the tissue sample and receive the blades. The fresh prostate gland is held in the cradle and the blades are moved through the cradle slits to produce multiple 4 mm slices of the gland in a plane perpendicular to its posterior surface. One of the resulting slices is preserved in RNAlater. The areas comprising tumour and normal glands within this preserved slice can be identified by matching it to the haematoxylin and eosin stained sections of the adjacent slices that are formalin fixed and paraffin wax embedded. Intact RNA can be extracted from the identified tumour and normal glands within the RNAlater preserved slice. Preoperative imaging studies are acquired with the angulation of axial images chosen to be similar to the slicing axis, such that stained sections from the formalin fixed, paraffin wax embedded slices match their counterparts on imaging.

CONCLUSIONS

A novel method of sampling fresh prostate removed at radical prostatectomy that allows tissue samples to be used both for diagnosis and molecular analysis is described. This method also allows the integration of preoperative imaging data with histopathological and molecular data obtained from the prostate tissue slices.

Towards biologically conformal radiation therapy (BCRT): Selective IMRT dose escalation under the guidance of spatial biology distribution

It is well known that the spatial biology distribution (e.g., clonogen density, radiosensitivity, tumor proliferation rate, functional importance) in most tumors and sensitive structures is heterogeneous. Recent progress in biological imaging is making the mapping of this distribution increasingly possible. The purpose of this work is to establish a theoretical framework to quantitatively incorporate the spatial biology data into intensity modulated radiation therapy (IMRT) inverse planning. In order to implement this, we first derive a general formula for determining the desired dose to each tumor voxel for a known biology distribution of the tumor based on a linear-quadratic model. The desired target dose distribution is then used as the prescription for inverse planning. An objective function with the voxel-dependent prescription is constructed with incorporation of the nonuniform dose prescription. The functional unit density distribution in a sensitive structure is also considered phenomenologically when constructing the objective function. Two cases with different hypothetical biology distributions are used to illustrate the new inverse planning formalism. For comparison, treatments with a few uniform dose prescriptions and a simultaneous integrated boost are also planned. The biological indices, tumor control probability (TCP) and normal tissue complication probability (NTCP), are calculated for both types of plans and the superiority of the proposed technique over the conventional dose escalation scheme is demonstrated. Our calculations revealed that it is technically feasible to produce deliberately nonuniform dose distributions with consideration of biological information. Compared with the conventional dose escalation schemes, the new technique is capable of generating biologically conformal IMRT plans that significantly improve the TCP while reducing or keeping the NTCPs at their current levels. Biologically conformal radiation therapy (BCRT) incorporates patient-specific biological information and provides an outstanding opportunity for us to truly individualize radiation treatment. The proposed formalism lays a technical foundation for BCRT and allows us to maximally exploit the technical capacity of IMRT to more intelligently escalate the radiation dose.

Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy

AIMS

To evaluate the prognostic significance of magnetic resonance imaging (MRI) tumour stage in clinically localised prostate cancer.

MATERIALS AND METHODS

Between 1988 and 1999, 199 men with clinically localised prostate cancer (T -T4, N0/Nx, M0) were treated with neo-adjuvant androgen deprivation and radical radiotherapy, and were staged using MRI. Concordance between clinical tumour (cT) stage, as determined by digital rectal examination, and MRI tumour (mT) stage was assessed. Univariate and multivariate analyses using the Cox proportional hazards model were used to study the prognostic role of cT stage and mT stage in addition to established prognostic factors.

RESULTS

Of these 199 patients, 103 (52%) were upstaged on MRI, seven (3%) were downstaged, and in 89 (45%) cT and mT stages were concordant. With median follow-up of 3.8 years, 5-year freedom from prostate-specific antigen (PSA) failure was 48% (95% confidence interval (CI) 39-56%). On univariate analysis, freedom from PSA failure was associated with mT stage (P = 0.009) as well as Gleason score (P < 0.001) and initial PSA (P < 0.001), but not cT stage (P = 0.449). On multivariate analysis, Gleason score (P = 0.001), initial PSA (P < 0.001), but not mT stage (P = 0.112) remained independent determinants of freedom from PSA failure. For the subgroup of 149 patients with cT1-2 disease, mT stage was a significant predictor of increased risk of PSA failure on univariate analysis (P = 0.005), but not multivariate analysis (P = 0.19).

CONCLUSION

Freedom from PSA failure was more closely associated with mT stage than cT stage. Future studies are warranted to determine whether mT stage is an independent determinant of treatment outcome.

Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy

Increased utilization of cross-sectional imaging has resulted in increased detection of incidental renal tumors. The noninvasive characterization of renal tissue has important implications for the diagnosis of renal malignancies and treatment monitoring. Recently, multiple breath-hold averaged proton magnetic resonance spectroscopy (1H-MRS) performed at high field has enabled the use of this noninvasive metabolic profiling technique for the investigation of the abdomen. Multiple breath-hold averaged 1H-MRS at high field (3T) was obtained in the kidneys of 10 healthy volunteers and in renal cell carcinoma tumors of 14 patients. The spectra of normal kidneys showed four main groups of resonances: 1) at 5.4–5.6 ppm, attributed to C6 of cholesterol and the unsaturated parts of the olefinic region of fatty acids; 2) at 4.7 ppm, attributed to the residual water signal; 3) at 3.2 ppm, attributed to trimethylamine moiety of choline metabolites; and 4) at 1.3 and 0.9 ppm, attributed to the methylenes and terminal methyls of lipids. The ratio of the signal at 5.4 ppm to that of 1.3 ppm was 19-fold lower in renal cell carcinomas than in healthy kidneys, tied P = 0.0003 Mann-Whitney U-test, suggesting a decrease in both free cholesterol and the degree of unsaturation of fatty acids in the malignant tissue. This metabolic shift is in agreement with previous ex vivo studies of human renal cell carcinoma. The ability to detect renal metabolic shifts noninvasively may improve the specificity of preoperative renal tissue characterization and may provide a new modality for treatment monitoring.

Seeing into cells. The promise of in vivo molecular imaging in oncology

The promise of in vivo molecular imaging in oncology

A DECREASE IN 1 H NUCLEAR MAGNETIC RESONANCE SPECTROSCOPICALLY DETERMINED CITRATE IN HUMAN SEMINAL FLUID ACCOMPANIES THE DEVELOPMENT OF PROSTATE ADENOCARCINOMA

PURPOSE

Because human prostatic fluid contributes almost 50% of the volume of seminal plasma and this fluid contains unique prostatic metabolites such as citrate, which are markedly altered during tumorigenesis, we investigated high resolution H nuclear magnetic resonance (NMR) spectroscopy of unprocessed human seminal plasma as a rapid, noninvasive diagnostic tool for prostate adenocarcinoma.

MATERIALS AND METHODS

Semen and prostatic massage samples from control and tumor bearing subjects were stored frozen at -20C and thawed prior to water suppressed NMR analysis. We found that freezing produced no significant alterations in the semen NMR spectra. Quantitative NMR spectroscopy was performed by first calibrating the water suppression data acquisition sequence with a series of standard samples containing known amounts of citrate within the physiological range.

RESULTS

Well resolved citrate resonances from the seminal plasma of 3 control subjects with prostate specific antigen (PSA) less than 1 ng/ml were integrated to give concentrations of 97 to 178 mM. Semen from a 47-year-old man with benign prostatic hyperplasia and a PSA of 5.5 ng/ml contained 156 mM citrate. In contrast, seminal plasma from 2 patients with prostate cancer, including a 46-year-old man with Gleason grade 8 and PSA 45.2 ng/ml, and a 64-year-old man with grade 6 and PSA 13.0 ng/ml, revealed citrate NMR signals corresponding to a concentration of only 28 and 24 mM, respectively. Spectra from prostatic massage fluid from a normal 23-year-old volunteer showed a citrate of 483 mM, while massage fluid from a 56-year-old patient with Gleason grade 4 cancer showed a citrate of only 1.35 mM.

CONCLUSIONS

To our knowledge this study is the first to use high resolution NMR of semen to diagnose prostate cancer. Given the known effects of adenocarcinoma on prostate metabolism, the study indicates that high resolution H NMR can be used to measure citrate in seminal fluid, potentially providing a new, rapid, noninvasive screening method.

Functional Characterization of Prostate Cancer by Integrated Magnetic Resonance Imaging and Oxygenation Changes During Carbogen Breathing

OBJECTIVE

The objective of this study was to evaluate the changes in oxygenation of prostate cancer induced by carbogen breathing using blood oxygen level-dependent (BOLD) magnetic resonance image (MRI) with an endorectal coil (eMRI).

MATERIALS AND METHODS

In 32 patients with biopsy-proven prostate cancer, endorectal MRI was performed at 1.5 Tesla using the BOLD method. Images were acquired during 4 x 4-minute episodes alternating between room air and carbogen (95% O2/5% CO2) breathing. In each episode, 40 images were acquired (T2*-weighted EPI sequence, 12-14 slices, 3-mm thickness). All patients underwent radical prostatectomy; BOLD-MRI findings were correlated with the histopathologic results.

RESULTS

BOLD-MRI could be evaluated in 29 patients, and revealed heterogeneous signal changes of normal prostate and cancer tissue similar to the heterogeneity of prostate tissue in anatomic/pathologic preparation. A significant signal intensity increase (P = 0.004) was found in normal central gland and peripheral zone during carbogen breathing. Signal enhancement in carcinoma was significantly lower (P = 0.004) compared with the contralateral normal side.

CONCLUSION

Intrinsic blood-tissue contrast-functional MRI during carbogen breathing may help detect and characterize prostate carcinoma from normal tissue, particularly in small 1-sided carcinomas. This may be useful for identifying candidates for radiotherapy and monitoring noninvasive therapeutic approaches.

Whole-body MRI at high field: technical limits and clinical potential

This review seeks to clarify the most important implications of higher magnetic field strength for clinical examinations of the whole body. An overview is provided on the resulting advantages and disadvantages for anatomical, functional and biochemical magnetic resonance examinations in different regions of the body. It is demonstrated that susceptibility-dependent imaging, chemical shift selective (e.g., fat-suppressed) imaging, and spectroscopic techniques clearly gain from higher field strength. Problems due to shorter wavelength and higher radio frequency energy deposition at higher field strength are reported, especially in examinations of the body trunk. Thorax examinations provided sufficient homogeneity of the radio frequency field for common examination techniques in most cases, whereas abdominal and pelvic imaging was often hampered by undesired dielectric effects. Currently available and potential future strategies to overcome related limitations are discussed. Whole-body MRI at higher field strength currently leads to clearly improved image quality using a variety of established sequence types and for examination of many body regions. But some major problems at higher field strength have to be solved before high-field magnetic resonance systems can really replace the well-established and technically developed magnetic resonance systems operating at 1.5 T for each clinical application.

Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning

High-resolution magic angle spinning (HRMAS) NMR spectroscopy has proven useful for analyzing intact tissue and permitting correlations to be made between tissue metabolites and disease pathologies. Extending these studies to slow-spinning methodologies helps protect tissue pathological structures from HRMAS centrifuging damage and may permit the study of larger objects. Spinning sidebands (SSBs), which are produced by slow spinning, must be suppressed to prevent the complication of metabolic spectral regions. In this study human prostate tissues, as well as gel samples of a metabolite mixture solution, were measured with continuous-wave (CW) water presaturation on a 14.1T spectrometer, with HRMAS spinning rates of 250, 300, 350, 600, and 700 Hz, and 3.0 kHz. Editing the spectra by means of a simple minimum function (Min(A, B, ..., N) for N spectra acquired at different but close spinning rates) produced SSB-free spectra. Statistically significant linear correlations were observed for metabolite concentrations quantified from the Min(A, B, ..., N)-edited spectra generated at low spinning rates, with concentrations measured from the 3 kHz spectra, and also with quantitative pathology. These results indicate the empirical utility of this scheme for analyzing intact tissue, which also may be used as an adjunct tool in pathology for diagnosing disease.

Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies

To assess the benefit of routinely used three-dimensional 1H-spectroscopy of the prostate combined with magnetic resonance imaging in patients with elevated prostate-specific antigen (PSA) levels and negative or no previous prostate biopsies. Fifty-four patients were examined with our combined imaging protocol, which consisted of transversal, coronal and sagittal T2-weighted fast spin echo sequences. For spectroscopy, we used a three-dimensional chemical shift imaging spin echo (3D-CSI-SE) sequence. The study population consisted of patients with elevated PSA levels and histologically proven prostate carcinoma and patients with elevated PSA levels and negative or no previous prostate biopsies. Examination time was 31 min, a time feasible for routine use. Eighty-eight tumour voxels and 67 control voxels of 27 patients with histologically proven prostate carcinoma were analysed. Ratios of (choline + creatine)/citrate [(Cho + Crea)/Cit] below 0.6 were classified as normal and above 0.6 as pathological. Applying this classification to 20 patients with tumour-suspicious lesions of the prostate and negative or no previous prostate biopsies, we could obtain a sensitivity and specificity for tumour detection of 100% and 69%, respectively. Our combined imaging protocol is feasible for routine use and can add valuable information for the diagnostic management of patients with negative or no previous prostate biopsies.

In vivo diffusion tensor imaging of the human prostate

This study demonstrates the feasibility of in vivo prostate diffusion tensor imaging (DTI) in human subjects. We implemented an EPI-based diffusion-weighted (DW) sequence with seven-direction diffusion gradient sensitization, and acquired DT images from six subjects using cardiac gating with a phased-array prostate surface coil operating in a linear mode. We calculated two indices to quantify diffusion anisotropy. The direction of the eigenvector corresponding to the leading eigenvalue was displayed by means of a color-coding scheme. The average diffusion values of the prostate peripheral zone (PZ) and central gland (CG) were 1.95 +/- 0.08 x 10(-3) mm2 s and 1.53 +/- 0.34 x 10(-3) mm2 s, respectively. The average fractional anisotropy (FA) values for the PZ and CG were 0.46 +/- 0.04 and 0.40 +/- 0.08, respectively. The diffusion ellipsoid in prostate tissue was anisotropic and approximated a prolate model, as shown in the color maps of the anisotropy. Consistent with the tissue architecture, the prostate fiber orientations were predominantly in the superior-inferior (SI) direction for both the PZ and CG. This study shows the feasibility of in vivo DTI and establishes normative DT values for six subjects.

System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner

A technique for transperineal high-dose-rate (HDR) prostate brachytherapy and needle biopsy in a standard 1.5 T MRI scanner is demonstrated. In each of eight procedures (in four patients with intermediate to high risk localized prostate cancer), four MRI-guided transperineal prostate biopsies were obtained followed by placement of 14-15 hollow transperineal catheters for HDR brachytherapy. Mean needle-placement accuracy was 2.1 mm, 95% of needle-placement errors were less than 4.0 mm, and the maximum needle-placement error was 4.4 mm. In addition to guiding the placement of biopsy needles and brachytherapy catheters, MR images were also used for brachytherapy treatment planning and optimization. Because 1.5 T MR images are directly acquired during the interventional procedure, dependence on deformable registration is reduced and online image quality is maximized.

Détection du cancer de la prostate par IRM endorectale dynamique et spectroscopique-proton

PURPOSE

Determine the feasibility of dynamic gadolinium enhanced MRI and spectroscopic imaging in routine clinical practice using standard equipment and its usefulness for patients with negative biopsies and high degree of suspicion of prostate cancer.

PATIENTS AND METHODS

Fifty five patients underwent endorectal MRI using T2W spin echo (SE) imaging, dynamic gadolinium enhanced imaging and proton spectroscopic imaging before repeat US-guided transrectal biopsies. The statistical analysis consisted in the correlation of the results obtained with each of the two MRI techniques and the results of the biopsies in the corresponding prostate lobe.

RESULTS

32 patients were included in the analysis. Biopsies revealed cancer for 15 patients. The statistical analysis showed a lack of significant correlation between T2W-SE imaging and biopsy results. A correlation with statistical significance was found between dynamic gadolinium enhanced imaging and biopsies (p=0,0018) and between spectroscopic imaging results and biopsies in the corresponding lobe (p=0,0001).

CONCLUSION

Endorectal MRI with a standard clinical equipment using dynamic gadolinium enhanced imaging and spectroscopic imaging may be used in clinical routine to improve detection and localization in prostate cancer compared to T2 weighted spin echo imaging.

Prostate Depiction at Endorectal MR Spectroscopic Imaging: Investigation of a Standardized Evaluation System

PURPOSE

To investigate the accuracy and interobserver variability of a standardized evaluation system for endorectal three-dimensional (3D) magnetic resonance (MR) spectroscopic imaging of the prostate.

MATERIALS AND METHODS

The human research committee approved the study, and all patients provided written informed consent. Endorectal MR imaging and MR spectroscopic imaging were performed in 37 patients before they underwent radical prostatectomy. For the 22 patients with good or excellent MR spectroscopic imaging data, step-section histopathologic tumor maps were used to identify spectroscopic voxels of unequivocally benign (n = 306) or malignant (n = 81) peripheral zone tissue. Two independent spectroscopists, unaware of all other findings, scored the spectra of the selected voxels by using a scale of 1 (benign) to 5 (malignant) that was based on standardized metabolic criteria. Descriptive statistical, receiver operating characteristics (ROC), and kappa statistical analyses of the data obtained by both readers were performed by using two definitions of cancer: one based on a voxel score of 3-5 and the other based on a score of 4 or 5.

RESULTS

The scoring system had good accuracy (74.2%-85.0%) in the differentiation between benign and malignant tissue voxels, with areas under the ROC curve of 0.89 for reader 1 and 0.87 for reader 2. Specificities of 84.6% and 89.3% were achieved when a voxel score of 4 or 5 was used to identify cancer, and sensitivities of 90% and 93% were achieved when a score of 3-5 was used to identify cancer. Readers demonstrated excellent interobserver agreement (kappa values, 0.79 and 0.80).

CONCLUSION

The good accuracy and excellent interobserver agreement achieved by using the standardized five-point scale to interpret peripheral zone metabolism demonstrate the potential effectiveness of using metabolic information to identify prostate cancer, and the clinical usefulness of this system warrants testing in prospective clinical trials of MR imaging combined with MR spectroscopic imaging.

Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer

PURPOSE

To characterize the metabolic response in the prostate, the time to resolution of disease, and the correlation between magnetic resonance imaging (MRI) with spectroscopy (MRSI) results, biopsy findings, and serum prostate-specific antigen (PSA) level after external beam radiotherapy.

METHODS AND MATERIALS

A total of 55 patients underwent MRSI before and/or at varying times after external beam radiotherapy. The percentage of the cancerous, healthy, and atrophic voxels was calculated, and the time to resolution of disease was determined and compared with the PSA nadir.

RESULTS

Of the 55 patients, 70% had negative MRSI and 30% had positive MRSI findings. A strong correlation was found between negative MRSI and negative biopsy findings (n = 11) and between positive MRSI and positive biopsy findings (n = 7). A weak correlation was observed between the PSA level and the MRSI and biopsy findings. The mean time to disease resolution was 40.3 months and the mean time to PSA nadir was 50 months. With time, an increase in atrophy and a decline in cancerous metabolism was found.

CONCLUSION

When used in conjunction with PSA measurement and biopsy, the results of this study suggest that MRSI contributes to a greater level of confidence in determining the outcome and may be a useful adjunct for assessing local control before PSA failure when striving to distinguish the benign "blip" from local recurrence.

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience

PURPOSE

To evaluate endorectal magnetic resonance (MR) imaging and MR spectroscopic imaging for the depiction of locally recurrent prostate cancer after external beam radiation therapy.

MATERIALS AND METHODS

Endorectal MR imaging and MR spectroscopic imaging were performed in 21 patients with biochemical failure after external beam radiation therapy for prostate cancer. Two readers independently and retrospectively reviewed MR images and rated the likelihood of recurrent tumor on a five-point scale. Spectroscopic voxels were considered suspicious for malignancy if the choline level was elevated and citrate was absent. Receiver operating characteristic curve analysis was used to assess cancer detection in each side of the prostate with endorectal MR imaging and spectroscopic imaging at different thresholds based on the scores assigned by the two readers and on the number of suspicious voxels in each hemiprostate, respectively. The presence or absence of cancer at subsequent transrectal biopsy was used as the standard of reference.

RESULTS

Biopsy demonstrated locally recurrent prostate cancer in nine hemiprostates in six patients. The area under the receiver operating characteristic curve for the detection of locally recurrent cancer with MR imaging was 0.49 and 0.51 for readers 1 and 2, respectively. By using the number of suspicious voxels to define different diagnostic thresholds, the area under the receiver operating characteristic curve for MR spectroscopic imaging was significantly (P < .005) higher, at 0.81. In particular, the presence of three or more suspicious voxels in a hemiprostate showed a sensitivity and specificity of 89% and 82%, respectively, for the diagnosis of local recurrence. Seven hemiprostates demonstrated complete metabolic atrophy at spectroscopic imaging and only postirradiation atrophy at biopsy.

CONCLUSION

Preliminary data suggest that MR spectroscopic imaging, but not endorectal MR imaging, may be of value for the depiction of locally recurrent prostate cancer after radiation therapy.

MRI-guided HDR prostate brachytherapy in standard 1.5T scanner

PURPOSE

Magnetic resonance imaging (MRI) provides superior visualization of the prostate and surrounding anatomy, making it the modality of choice for imaging the prostate gland. This pilot study was performed to determine the feasibility and dosimetric quality achieved when placing high-dose-rate prostate brachytherapy catheters under MRI guidance in a standard "closed-bore" 1.5T scanner.

METHODS AND MATERIALS

Patients with intermediate-risk and high-risk localized prostate cancer received MRI-guided high-dose-rate brachytherapy boosts before and after a course of external beam radiotherapy. Using a custom visualization and targeting program, the brachytherapy catheters were placed and adjusted under MRI guidance until satisfactory implant geometry was achieved. Inverse treatment planning was performed using high-resolution T(2)-weighted MRI.

RESULTS

Ten brachytherapy procedures were performed on 5 patients. The median percentage of volume receiving 100% of prescribed minimal peripheral dose (V(100)) achieved was 94% (mean, 92%; 95% confidence interval, 89-95%). The urethral V(125) ranged from 0% to 18% (median, 5%), and the rectal V(75) ranged from 0% to 3.1% (median, 0.3%). In all cases, lesions highly suspicious for malignancy could be visualized on the procedural MRI, and extracapsular disease was identified in 2 patients.

CONCLUSION

High-dose-rate prostate brachytherapy in a standard 1.5T MRI scanner is feasible and achieves favorable dosimetry within a reasonable period with high-quality image guidance. Although the procedure was well tolerated in the acute setting, additional follow-up is required to determine the long-term safety and efficacy of this approach.

MR imaging and MR spectroscopic imaging of prostate cancer

The primary indication for prostate MR and MR spectroscopic imaging is evaluating men with newly diagnosed prostate cancer who are deciding whether to undergo surgery or radiotherapy. Other applications of MR and MR spectroscopic imaging in prostate cancer are not defined fully. Areas of research include volumetric localization of prostate cancer, in vivo MR spectroscopic imaging at high field strength, in vitro MR spectroscopic imaging at very high field strength, novel spectroscopic markers of malignancy,and interventional MR guidance of biopsy and therapy. MR spectroscopic imaging remains a relatively novel technique, and successful implementation is demanding. Nonetheless, only MR and MR spectroscopic imaging allow structural and metabolic evaluation of prostate cancer location, aggressiveness, and stage, and MR imaging provides clinically and therapeutically relevant information on prostatic and periprostatic anatomy.

Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging

PURPOSE

To characterize the time to metabolic atrophy (TMA) after permanent prostate implantation (PPI) using combined MRI and magnetic resonance spectroscopic imaging (MRSI) compared with the time to prostate-specific antigen (PSA) nadir.

METHODS AND MATERIALS

This study was based on a posttreatment analysis comparing the MRI/MRSI findings with the PSA levels of 65 patients treated with PPI alone or combined with external beam radiotherapy and/or HT. The fraction of interpretable voxels demonstrating metabolic atrophy was used to compare the TMA with the time to PSA nadir.

RESULTS

The fraction of patients with metabolic atrophy in >95% of usable voxels after PPI increased from approximately 46% to 100% at 6 and 48 months, respectively. The mean time for PSA nadir vs. TMA was 42.5 vs. 28.9 months (PPI), 32.8 vs. 25.6 months (external beam radiotherapy + PPI), and 25.3 vs. 28.0 months (external beam radiotherapy + hormonal therapy + PPI).

CONCLUSION

Magnetic resonance spectroscopic imaging may provide an early tool for evaluating the treatment response for patients treated with PPI. If supported by longer follow-up, TMA may be a useful adjunct to PSA measurement for assessing local control after PPI and could be useful in evaluating the complex relationships between the quality of the implant and the time to indication of successful therapy.

A comparative study of myo-inositol quantification using lcmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain

Myo-inositol is a strongly coupled system and resonates at four chemical shift positions. At 1.5 T, only the singlet component at 3.57 ppm is detected. However, at 3 T this resonance is resolved into its components at 3.55 ppm and 3.61 ppm. Due to the increased spectral resolution and signal-to-noise ratio, it is anticipated that the quantification of myo-inositol should improve at 3 T. Using data from normal controls and the LCmodel quantification procedure, we found that the quantification precision, reproducibility and detection sensitivity of myo-inositol is significantly better at 3 T relative to 1.5 T.

Proton high-resolution magic angle spinning NMR analysis of fresh and previously frozen tissue of human prostate

The previously observed improvement in spectral resolution of tissue proton NMR with high-resolution magic angle spinning (HRMAS) was speculated to be due largely to freeze-thawing artifacts resulting from tissue storage. In this study, 12 human prostate samples were analyzed on a 14.1T spectrometer at 3 degrees C, with HRMAS rates of 600 and 700 Hz. These samples were measured fresh and after they were frozen for 12-16 hr prior to thawing. The spectral linewidths measured from fresh and previously frozen samples were identical for all metabolites except citrate and acetate. The metabolite intensities of fresh and freeze-thawed samples depend on the quantification procedures used; however, in this experiment the differences of means were <30%. As expected, it was found that tissue storage impacts tissue quality for pathological analysis, and HRMAS conditions alone are not sufficiently destructive to impair pathological evaluation. Furthermore, although storage conditions affect absolute metabolite concentrations in NMR analysis, relative metabolite concentrations are less affected.

Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues

Proton high-resolution magic angle spinning ((1)H HR-MAS) NMR spectroscopy and quantitative histopathology were performed on the same 54 MRI/3D-MRSI-targeted postsurgical prostate tissue samples. Presurgical MRI/3D-MRSI targeted healthy and malignant prostate tissues with an accuracy of 81%. Even in the presence of substantial tissue heterogeneity, distinct (1)H HR-MAS spectral patterns were observed for different benign tissue types and prostate cancer. Specifically, healthy glandular tissue was discriminated from prostate cancer based on significantly higher levels of citrate (P = 0.04) and polyamines (P = 0.01), and lower (P = 0.02) levels of the choline-containing compounds choline, phosphocholine (PC), and glycerophosphocholine (GPC). Predominantly stromal tissue lacked both citrate and polyamines, but demonstrated significantly (P = 0.01) lower levels of choline compounds than cancer. In addition, taurine, myo-inositol, and scyllo-inositol were all higher in prostate cancer vs. healthy glandular and stromal tissues. Among cancer samples, larger increases in choline, and decreases in citrate and polyamines (P = 0.05) were observed with more aggressive cancers, and a MIB-1 labeling index correlated (r = 0.62, P = 0.01) with elevated choline. The elucidation of spectral patterns associated with mixtures of different prostate tissue types and cancer grades, and the inclusion of new metabolic markers for prostate cancer may significantly improve the clinical interpretation of in vivo prostate MRSI data.

1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration

The objective of this study was to establish in vivo (1)H-magnetic resonance (MR) spectroscopic appearances of cervical cancer using an endovaginal receiver coil and corroborate findings with magic angle spinning (MAS) MR spectroscopy of tissue samples. Fifty-three women (14 controls and 39 with cervical cancer) underwent endovaginal coil MR imaging at 1.5 T with T(1)- and T(2)-weighted scans sagittal and transverse to the cervix. Localized (1)H MR spectra (PRESS technique, TR 1600 ms, TE 135 ms) were accumulated in all controls and 29 cancer patients whose tumour filled > 50% of a single 3.4 cm(3) voxel. Peaks from triglyceride-CH(2) and -CH(3) were defined as present and in-phase (with the choline resonance), present but out-of-phase, or not present. Peak areas of choline-containing compounds were standardized to the area of unsuppressed tissue water resonance. Comparisons in observed resonances between groups were made using Fisher's exact test (qualitative data) and a t-test (quantitative data). Biopsies from these women analysed using MAS-MR spectroscopy and normalized to the intensity of an external standard of silicone rubber were similarly compared. Adequate water suppression permitted spectral analysis in 11 controls and 27 cancer patients. In-phase triglyceride-CH(2) resonances (1.3 ppm) were observed in 74% of tumours but in no control women (p < 0.001). No differences were observed in the presence of a 2 ppm resonance, choline-containing compounds or creatine in cancer compared with control women. However, ex vivo analysis showed significant differences not only in -CH(2), but also in -CH(3), a 2 ppm resonance, choline-containing compounds and creatine between tissues from control women and cancer tissue (p < 0.001, = 0.001, = 0.036, < 0.001 and = 0.004 respectively). On in vivo (1)H-MR spectroscopy, the presence of positive triglyceride-CH(2) resonances can be used to detect and confirm the presence of cervical cancer. However, technical improvements are required before routine clinical use.

Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue

PURPOSE

To determine if the apparent diffusion coefficient (ADC) can discriminate benign from malignant peripheral zone (PZ) tissue in patients with biopsy-proven prostate cancer that have undergone endorectal diffusion-weighted imaging (DWI) of the prostate.

MATERIALS AND METHODS

Ten patients with prostate cancer underwent endorectal magnetic resonance imaging (MRI) in addition to DWI. A two-dimensional grid was placed over the axial images, and each voxel was graded by a 4-point rating scale to discriminate nonmalignant from malignant PZ tissue based on MR images alone. ADC was then determined for each voxel and plotted for nonmalignant and malignant voxels for the entire patient set. Second, with the radiologist aware of biopsy locations, any previously assigned voxel grade that was inconsistent with biopsy data was regrouped and ADCs were replotted.

RESULTS

For the entire patient set, without and with knowledge of the biopsy data, the mean ADCs for nonmalignant and malignant tissue were 1.61 +/- 0.27 and 1.34 +/- 0.38 x 10(-3) mm2/second (P = 0.002) and 1.61 +/- 0.26 and 1.27 +/- 0.37 x 10(-3) mm2/second (P = 0.0005), respectively.

CONCLUSION

DWI of the prostate is possible with an endorectal coil. The mean ADC for malignant PZ tissue is less than nonmalignant tissue, although there is overlap in individual values.

Dynamic Magnetic Resonance Tomography and Proton Magnetic Resonance Spectroscopy of Prostate Cancers in Rats Treated by Radiotherapy

RATIONALE AND OBJECTIVES

To establish an experimental setting for monitoring perfusion and metabolism in orthotopic prostate cancer at 1.5 T using dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) and 1H-MR spectroscopy (MRS).

METHODS

Dunning rat prostate cancer cells were injected into the prostate by open surgery. Twelve tumor-bearing rats (5 of these irradiated) and 6 healthy controls were followed up using gadolinium-diethylenetriaminepentaacetic acid -enhanced dynamic MRI and 1H-MRS. Amplitude and the exchange rate constant kep were calculated (2-compartment model). From 1H-MR spectra, ratios of choline (Cho) and creatine (tCr) were calculated. All tumors were examined histologically.

RESULTS

On DCE MRI parameter maps, tumors showed increased vascularization. kep and microvessel density were correlated (r = 0.97). Tumors showed elevated Cho/tCr and an unexpected lipid fraction (2.0-2.2 parts per million). Irradiation slowed tumor growth significantly. Changes of perfusion and metabolism could be detected in all tumors during follow up.

CONCLUSION

DCE MRI and 1H-MRS has potential to characterize orthotopic Dunning prostate cancer in rats, which is a promising model similar to human prostate carcinomas.

Magnetic Resonance Imaging and Spectroscopic Imaging of Prostate Cancer

PURPOSE

We describe the practical technical aspects of magnetic resonance spectroscopic imaging (MRSI), and summarize the current and potential future status of magnetic resonance imaging (MRI) and MRSI in the diagnosis, localization, staging, treatment planning and post-treatment followup of prostate cancer.

MATERIALS AND METHODS

Contemporary series of patients with prostate cancer evaluated by MRI and MRSI were reviewed, with particular respect to imaging accuracy as evaluated by histopathological correlation, and the relationship between MRI and MRSI and outcome.

RESULTS

MRI and MRSI have a limited role in prostate cancer diagnosis but may be helpful for patients with a high index of suspicion and negative initial biopsy. High specificity can be achieved for sextant localization of cancer when sextant biopsy, MRI and MRSI are all positive. Volumetric localization is of limited accuracy for tumors less than 0.5 cc. Staging by MRI, which is improved by the addition of MRSI, is of incremental prognostic significance for patients with moderate and high risk tumors. MRI and MRSI may assist in surgical and radiation treatment planning, and posttreatment followup. In particular, the use of MRI to assist radiation treatment planning has been shown to improve outcome. Interventional MRI guided biopsy and therapy remain under investigation.

CONCLUSIONS

Only MRI and MRSI allow combined structural and metabolic evaluation of prostate cancer location, aggressiveness and stage. MRI provides clinically and therapeutically relevant anatomical information. The technology remains in evolution, and continued advances in accuracy and use are likely.

Preoperative staging of colorectal cancer--computed tomography and magnetic resonance imaging

Cross-sectional imaging techniques are increasingly being used in the preoperative evaluation of patients with colorectal cancer. Both computed tomography (CT) and magnetic resonance (MR) imaging have been improved with significant advances of the technological hard- and software. This has contributed to high patient acceptance due to shorter examination times and more open configuration of the systems, consistent high quality images with better delineation of the normal abdomino-pelvic anatomy and pathology. New techniques such as CT-colonography have emerged from a research application to a clinical tool which can be used in different clinical settings. Phased-array receiver coils have significantly increased the usefulness of MR in the evaluation of rectal neoplasms due to the high resolution that can be obtained. New organ specific contrast agents for magnetic resonance imaging have facilitated the preoperative evaluation of liver metastases in favour of more invasive techniques with similar sensitivities. However, preoperative staging criteria for colorectal cancer using computed tomography and magnetic resonance imaging has to be updated and the results of new techniques have to be confirmed in large trials. In the future, further development of CT and MR may offer 'one-stop-shopping' protocols for both diagnosis, local and distant staging of colorectal cancer. Diffusion weighted MR-imaging, in vivo spectroscopy as well as further targeted imaging, such as with lymph node specific agents for MR may also prove to be helpful in the preoperative evaluation of patients with colorectal cancer.

Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints

High-risk localized prostate cancer remains a vexing problem for clinicians. Definitive local treatments such as surgery and radiation therapy cure only a minority of these patients. As a result, efforts are being made to reduce the risk of recurrence by using chemotherapy and new agents before, during or after definitive local therapy. Neoadjuvant androgen deprivation therapy has yielded disappointing results when combined with surgery. Chemotherapy in the management of localized disease is evolving, and preliminary studies are just now being completed. Although these agents have established activity and acceptable toxicity in the hormone-refractory setting, more extensive use of them in patients with androgen-dependent disease will require data from randomized studies to determine overall efficacy. New molecular-targeted therapies are promising and hold the greatest hope that outcomes in early disease may be improved with early use of systemic therapy. The neoadjuvant surgical model also has promise in assessing the activity of new drugs, because it provides a means to determine molecular effects of specific agents, along with standard pathologic and clinical parameters of efficacy.

Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective

With increasing use of prostate-specific antigen as a screening tool, diagnosis of prostate cancer has undergone a stage migration toward early-stage disease. Although this has increased the proportion of men who are candidates for definitive, potentially curative therapy, it has also made clear the limitations of our current standard of care. Specifically, despite adequate local therapy, a significant proportion of men go on to develop progressive disease. Neoadjuvant systemic therapy is one approach that continues to be studied as a way to maximize cure rates in the setting of early-stage disease. This article reviews the current data regarding neoadjuvant therapy, both hormonal and chemotherapy, and discusses which men are appropriate candidates for this option.

Post-traumatic oedema of the foot after tibial fracture

A total of 97 patients with diaphyseal tibial fractures treated with functional bracing were studied prospectively. Persistent ipsilateral foot swelling was present in 84.5 per cent of the patients. Most of the swellings subsided with time, but a small percentage of them persisted for a duration of 2 years or more after injury. The time for disappearance of the swelling in 50 per cent of the patients was 18.6 weeks. The development of oedema is not related to the age and sex of the patients, the configuration, type and level of the fractures, or the association of a fibular fracture. The bone healed quicker in those who did not have swelling of the foot. Once the swelling has developed, it seems to run its own course and its disappearance is not related to the age and sex, the configuration, type and level of fractures, the association of a fibular fracture, or the time for fracture healing. This complication does not have any adverse effect on the functional recovery of the patients.